| Thalidomide for treatment of refractory epilepsy. | |
| | |
MedLine Citation:
|
PMID: 21035311 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
We have experimentally shown that thalidomide has strong anticonvulsant properties. In an open label study, eight male patients with refractory epilepsy received thalidomide at daily-doses of 200 mg during 1 year, frequency of seizures before and during treatment were compared. The mean number of seizures before thalidomide administration was 26 ± 4 per month; it decreased to 7 ± 1 along thalidomide therapy. Our results indicate that thalidomide has strong therapeutic effects in refractory epilepsy. |
| | |
Authors:
|
Guadalupe Palencia; Iris E Martinez-Juarez; Alejandra Calderon; Carol Artigas; Julio Sotelo |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-28 |
Journal Detail:
|
Title: Epilepsy research Volume: 92 ISSN: 1872-6844 ISO Abbreviation: Epilepsy Res. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8703089 Medline TA: Epilepsy Res Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 253-7 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
Neuroimmunology Unit, National Institute of Neurology and Neurosurgery of Mexico, Mexico. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Risk factors of neurosensory deficits in lower third molar surgery: an literature review of prospect...
Next Document: The epidemiology of epilepsy in the Russian Federation.